Practical implementation of automated closed-loop insulin delivery: A French position statement

Archive ouverte

Tubiana-Rufi, N. | Schaepelynck, P. | Franc, S. | Chaillous, Lucy | Joubert, M. | Renard, Eric | Reznik, Y. | Abettan, C. | Bismuth, E. | Beltrand, J. | Bonnemaison, E. | Borot, S. | Charpentier, G. | Delemer, B. | Desserprix, A. | Durain, D. | Farret, Anne | Filhol, N. | Guerci, B. | Guilhem, I. | Guillot, C. | Jeandidier, N. | Lablanche, S. | Leroy, R. | Melki, V. | Munch, M. | Penfornis, A. | Picard, S. | Place, Jérôme | Riveline, J.P. | Serusclat, P. | Sola-Gazagnes, A. | Thivolet, C. | Hanaire, H. | Benhamou, P.Y.

Edité par CCSD ; Elsevier Masson -

International audience. Automated closed-loop (CL) insulin therapy has come of age. This major technological advance is expected to significantly improve the quality of care for adults, adolescents and children with type 1 diabetes. To improve access to this innovation for both patients and healthcare professionals (HCPs), and to promote adherence to its requirements in terms of safety, regulations, ethics and practice, the French Diabetes Society (SFD) brought together a French Working Group of experts to discuss the current practical consensus. The result is the present statement describing the indications for CL therapy with emphasis on the idea that treatment expectations must be clearly defined in advance. Specifications for expert care centres in charge of initiating the treatment were also proposed. Great importance was also attached to the crucial place of high-quality training for patients and healthcare professionals. Long-term follow-up should collect not only metabolic and clinical results, but also indicators related to psychosocial and human factors. Overall, this national consensus statement aims to promote the introduction of marketed CL devices into standard clinical practice.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion